Asgard Therapeutics

Series-A
asgardthx.com Biotech & Healthcare
Total Funding $30M
Latest Round $30M Series-A
Last Announced Mar 14, 2024
Investors Undisclosed
Decision Makers 6 Verified

About Asgard Therapeutics

Develops cancer immunotherapies using direct cell reprogramming technologies.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website asgardthx.com
Domain Registered Date Jan 5, 2019

Social & Network Presence

X / Twitter Profile @AsgardThx (292 followers) Created on Dec 2018
LinkedIn Corporate Not linked

Company Milestones & Timeline

4 Events
  1. Capital Raise

    Raised $30,000,000 · Series-A

    fundraisingfox.com

  2. Capital Raise

    Seed announced

    fundraisingfox.com

  3. Milestone

    Website domain registered

    asgardthx.com

  4. Milestone

    X account created (@AsgardThx)

    292 followers

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Asgard Therapeutics.

Funding History

2 Rounds
Series-A · Mar 14, 2024
Seed · Nov 21, 2021

Founders & Leadership

2

Cristiana Pires

Co-founder and CEO

Work email & phone locked Unlock →

Fábio Rosa

Co-founder and VP of Research

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts